Back to Search
Start Over
Challenges to Data Monitoring Committees When Regulatory Authorities Intervene.
- Source :
-
New England Journal of Medicine . 4/21/2016, Vol. 374 Issue 16, p1580-1584. 5p. - Publication Year :
- 2016
-
Abstract
- During ATMOSPHERE, a trial comparing aliskiren, enalapril, or both for heart failure, two other trials suggested harm from aliskiren in patients with diabetes, and regulators stopped aliskiren in such patients in ATMOSPHERE. The data monitoring committee suggests that regulators should trust the DMC to ensure patient safety in a clinical trial. The trial sponsor (Novartis) and the regulatory agencies have responded in letters to the editor. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00284793
- Volume :
- 374
- Issue :
- 16
- Database :
- Academic Search Index
- Journal :
- New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 114704918
- Full Text :
- https://doi.org/10.1056/NEJMsb1601674